Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » Patient Stories » Simon, VIC

Simon, VIC

Simon’s Story – Living with VHL

I was 26, newly married and celebrating my honeymoon when I was hit with crippling headaches. What I thought was stress turned out to be a brain tumour the size of a golf ball.

After emergency surgery and a second operation due to a brain bleed, I was left permanently deaf in one ear, with chronic tinnitus and facial pain that hasn’t gone away. I spent two months in hospital learning to walk, eat and drink again. It looked like the worst was behind me.

But ten years later, back pain led to a shocking diagnosis: Von Hippel-Lindau syndrome (VHL), a rare genetic condition that causes tumours to grow throughout the body—brain, spine, kidneys, pancreas, and more. Since then, I’ve endured multiple spinal and brain surgeries, and radiation for tumours that couldn’t be removed.

Since 2020, I’ve had surgery every year. VHL doesn’t stop. It keeps coming. And each time, the risks get bigger—paralysis, disability, even death. You live in a constant state of uncertainty.

Then I learned about Belzutifan, a drug that could shrink tumours and reduce the need for ongoing surgery. It offered hope—but at $12,000 a month, it was out of reach for most patients. We made the tough decision to draw down on our mortgage to cover the cost. I was lucky. Most people with VHL are not.

But thanks to persistent advocacy from patients, families, and organisations like NeuroEndocrine Cancer Australia, Belzutifan is now listed on the Pharmaceutical Benefits Scheme. I now pay just $30 a month for a drug that has shrunk my tumours by more than 66 per cent. My surgeon was amazed.

This drug has given me breathing room. A chance to delay more surgery. A chance to live.

But while this is a massive step forward, it’s not the end of the journey. We need greater awareness of VHL, better education for healthcare professionals, and up-to-date resources to guide patients through diagnosis and care.

This condition is rare—but for those of us living with it, the impact is lifelong.

I’ll keep sharing my story so no one else has to wait as long as I did for answers—and hope.

Patient Stories

Lana, NSW

Blurry vision had led to a diagnosis of Von Hippel-Lindau (VHL) disease – a condition where multiple tumours grow in various parts of the body, including the brain, spinal cord, abdominal organs, and eyes.

Vanessa, ACT

I was in my late twenties when I first realised something wasn’t right. I began experiencing numbness in my back, and after months of tests and uncertainty, doctors discovered a cluster of tumours in my spine. That’s when I was diagnosed with VHL.

Patricia, NSW

There’s such little awareness about this cancer, even among medical professionals. I’ve had GPs say to me, “I’ve never seen a neuroendocrine cancer patient in my life.” And I tell them, “You probably have — you just didn’t diagnose them.”

Jo, QLD

In that moment, everything just crumbled. One minute, I was thinking I’d be home in a day or two. The next, I was being told I had stage-four, inoperable cancer.

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin